Unlabelled: ABSTRACTCanadian older adults with complex health problems are often considered ineligible for traditional rehabilitation programs but may benefit from slow stream rehabilitation (SSR). This scoping review summarizes the literature related to SSR for older adults, within single-payer health care systems.
Methods: Peer-reviewed and grey-literature documents relevant to older adults in SSR were systematically reviewed.
Results: 1,445 documents were screened independently by two reviewers [Cohen Kappa value of 0.78 (CI = 0.73, 0.83)], and included 18 documents. SSR programs were found to be multidisciplinary with a mean duration ranging from 30 to 141.2 days. SSR participants were more likely to be female, with a mean age range of 72-82 years, multiple co-morbidities and mild-to-moderate cognitive impairments. SSR participants demonstrated improvements in physical and functional measures.
Discussion: SSR programs have the potential to be an integral part of the continuum of care for older adults with complex medical histories.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1017/S0714980818000740 | DOI Listing |
J Pediatr Endocrinol Metab
January 2025
Department of Pediatric Endocrinology, Kocaeli City Hospital, Kocaeli, Türkiye.
Objectives: This study aimed to identify clinical features of girls referred to a pediatric endocrinology clinic for suspected precocious puberty, differentiate true precocious puberty from other variants, evaluate treatment status, and identify distinguishing factors between patient groups.
Methods: We retrospectively evaluated the records of 275 consecutive girls aged 0-10 years referred for suspected precocious puberty.
Results: Among the patients, 30 (10.
J Binocul Vis Ocul Motil
January 2025
Eye Center, Sanno Hospital, Tokyo, Japan.
Purpose: To investigate changes in eye alignment before and after ICL implantation in patients with myopia having corrected distance visual acuity (CDVA) of ≥0.0 logMAR.
Subjects And Methods: The medical records of 1012 patients without eye movement limitation who underwent bilateral ICL implantation were retrospectively reviewed a at the Eye Center of Sanno Hospital in Japan.
Spine (Phila Pa 1976)
January 2025
Department of Neurological Surgery, Washington University, St. Louis, MO, USA.
Study Design: Prospective cohort study.
Objective: This study aims to define Substantial Clinical Benefit (SCB) thresholds for PROMIS physical function (PF) and pain interference (PI) in lumbar or thoracolumbar spine surgery population.
Summary Of Background Data: Patient-reported outcome measures (PROMs) are widely used in spine surgery to assess treatment efficacy.
Arterioscler Thromb Vasc Biol
January 2025
Cardiovascular Medicine Unit, Department of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. (A.S., R.M.F., F.M.v.H.).
Background: Binding of ANGPTL (angiopoietin-like protein)-3 to ANGPTL8 generates a protein complex (ANGPTL3/8) that strongly inhibits LPL (lipoprotein lipase) activity, as compared with ANGPTL3 alone, suggesting that ANGPTL3/8 concentrations are critical for the regulation of circulation lipoprotein concentrations and subsequent increased coronary heart disease (CHD) risk. To test this hypothesis in humans, we evaluated the associations of circulating free ANGPTL3 and ANGPTL3/8 complex concentrations with lipoprotein concentrations and CHD risk in 2 prospective cohort studies.
Methods: Fasting blood samples were obtained in conjunction with the baseline evaluation of 9479 subjects from 2 population-based Swedish cohorts of middle-aged men and women.
Hematology
December 2025
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's Republic of China.
Objective: To evaluate the short-term efficacy and safety of eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in China.
Method: Data were retrospectively collected from patients with PNH who received at least 3 months of full-dose eculizumab. Changes in clinical and laboratory indicators after 1, 3, and 6 months of eculizumab therapy and at the end of follow-up were documented.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!